Cellectis Competitors

Cellectis (NASDAQ:CLLS) and NantKwest (NASDAQ:NK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Risk and Volatility

Cellectis has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cellectis and NantKwest's top-line revenue, earnings per share and valuation.

NantKwest has lower revenue, but higher earnings than Cellectis. NantKwest is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

33.3% of Cellectis shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 71.7% of NantKwest shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cellectis and NantKwest's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Cellectis and NantKwest, as reported by MarketBeat.

Cellectis currently has a consensus target price of $24.25, indicating a potential upside of 6.88%. NantKwest has a consensus target price of $18.00, indicating a potential downside of 45.95%. Given Cellectis' higher probable upside, equities research analysts clearly believe Cellectis is more favorable than NantKwest.

Summary

Cellectis beats NantKwest on 8 of the 14 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Cellectis (NASDAQ:CLLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Relay Therapeutics and Cellectis' gross revenue, earnings per share and valuation.

Relay Therapeutics has higher earnings, but lower revenue than Cellectis.

Institutional and Insider Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 33.3% of Cellectis shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Relay Therapeutics and Cellectis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Relay Therapeutics and Cellectis, as provided by MarketBeat.com.

Relay Therapeutics currently has a consensus price target of $57.40, indicating a potential upside of 42.82%. Cellectis has a consensus price target of $24.25, indicating a potential upside of 6.88%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than Cellectis.

Summary

Relay Therapeutics beats Cellectis on 7 of the 9 factors compared between the two stocks.

NanoString Technologies (NASDAQ:NSTG) and Cellectis (NASDAQ:CLLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Risk & Volatility

NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.59, indicating that its stock price is 159% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NanoString Technologies and Cellectis, as provided by MarketBeat.com.

NanoString Technologies currently has a consensus price target of $55.8333, indicating a potential downside of 24.91%. Cellectis has a consensus price target of $24.25, indicating a potential upside of 6.88%. Given Cellectis' higher probable upside, analysts plainly believe Cellectis is more favorable than NanoString Technologies.

Earnings and Valuation

This table compares NanoString Technologies and Cellectis' gross revenue, earnings per share and valuation.

NanoString Technologies has higher revenue and earnings than Cellectis. NanoString Technologies is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NanoString Technologies and Cellectis' net margins, return on equity and return on assets.

Institutional and Insider Ownership

98.3% of NanoString Technologies shares are held by institutional investors. Comparatively, 33.3% of Cellectis shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cellectis (NASDAQ:CLLS) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings for Cellectis and Revolution Medicines, as provided by MarketBeat.

Cellectis presently has a consensus price target of $24.25, indicating a potential upside of 6.88%. Revolution Medicines has a consensus price target of $46.75, indicating a potential upside of 1.65%. Given Cellectis' higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Revolution Medicines.

Valuation and Earnings

This table compares Cellectis and Revolution Medicines' gross revenue, earnings per share and valuation.

Revolution Medicines has higher revenue and earnings than Cellectis.

Profitability

This table compares Cellectis and Revolution Medicines' net margins, return on equity and return on assets.

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Cellectis on 6 of the 11 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Volatility & Risk

Cellectis has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Cellectis and Editas Medicine, as provided by MarketBeat.

Cellectis presently has a consensus price target of $24.25, indicating a potential upside of 6.88%. Editas Medicine has a consensus price target of $49.7778, indicating a potential upside of 6.16%. Given Cellectis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cellectis is more favorable than Editas Medicine.

Valuation and Earnings

This table compares Cellectis and Editas Medicine's gross revenue, earnings per share and valuation.

Cellectis has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cellectis and Editas Medicine's net margins, return on equity and return on assets.

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 0.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cellectis beats Editas Medicine on 9 of the 13 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Volatility & Risk

Cellectis has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, indicating that its share price is 170% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Cellectis and Sorrento Therapeutics, as provided by MarketBeat.

Cellectis presently has a consensus price target of $24.25, indicating a potential upside of 6.88%. Sorrento Therapeutics has a consensus price target of $28.75, indicating a potential upside of 180.49%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than Cellectis.

Valuation and Earnings

This table compares Cellectis and Sorrento Therapeutics' gross revenue, earnings per share and valuation.

Cellectis has higher earnings, but lower revenue than Sorrento Therapeutics. Cellectis is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cellectis and Sorrento Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sorrento Therapeutics beats Cellectis on 8 of the 14 factors compared between the two stocks.